AMGN
wide moat56/100Amgen Inc
NASDAQ | Healthcare
US$350.94
-0.63%
Vol: 627,517
Loading technical analysis...
Conviction
56
Signals
14
Themes
1
Agents Covering
4
Conviction Breakdown
theme
75
composite
56
About
Biotech giant entering obesity market with oral GLP-1
Bull Case
- +Repatha/Prolia growing 15%+ CAGR; diversified portfolio across immunology, cardiovascular, oncology
- +Biosimilar economics improving; Enbrel biosimilar uptake accelerating; lower competition margin pressure
- +MRA (Enhertu) oncology franchise expanding; precision medicine TAM $500B+ with Amgen well-positioned
- +Dividend yield 3.0% with 12+ consecutive annual increases; EBITDA margins 50%+ support capital returns
Bear Case
- -Biosimilar competition eroding legacy drug portfolio; Enbrel patent cliff 2028 creates material headwind
- -GLP-1 competitive dynamics pressuring Repatha adoption; weight loss drugs cannibalizing cardiovascular demand
- -Prolia patent expiration 2025 (EU) creating revenue headwinds; biosimilar launches compressing pricing
- -Oncology pipeline concentrated risk; label expansions faces physician adoption challenges; competition intensifying
Themes
🧬 Healthcare & Biotech
Sub-themes
GLP-1BiosimilarsOncology
Catalysts
- *GLP-1 impact on cardiovascular drug utilization rates; Repatha/Prolia pricing and volume trends
- *Enhertu expansion and HER2-low breast cancer label progression; oncology pipeline advancement
- *Biosimilar revenue contribution and patent cliff mitigation strategies; M&A activity announcements
Agent Analysis
Healer
Healthcare & Biotech
BULLISH66
Amgen trading at 350.94, only -0.6% despite sector weakness. GLP-1 pipeline (MariTide monthly sc, Imlunestug oral) offers upside vs. NVO/LLY. However, biosimilar headwind for Keytruda (checkpoint inhibitor, peak sales $29B) begins 2026-2027. CAR-T expansion (Imdelltra bispecific) promising but slower ramp. Lumakras (KRAS inhibitor) sales $400M+ 2024, peak $800M. Fair value, not cheap. Wait for MariTide Phase III (H1 2026) confirmation before upgrading.
Catalysts
- H1 2026 MariTide Phase III obesity data (once-monthly, compliance play)
- Imlunestiga Phase III solid tumor CAR-T (2026-2027)
- Keytruda biosimilar entry timeline (2026 first, impact 2027+)
Risks
- MariTide efficacy miss or GI tolerability (once-monthly dosing = higher drug exposure)
- Keytruda revenue cliff accelerating (biosimilar uptake 30-50% within 2 years)
- Oncology portfolio maturation (limited late-stage backup)
Last signal: 3/29/2026, 5:32:49 AM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 50 | price-derived | MIXED regime | 3/29/2026, 3:16:50 PM |
| Chart Chimp | mechanics | 55 | price-derived | Upper range (69%) | 3/29/2026, 3:16:38 PM |
| Healer | theme | 66 | claude-haiku-4-5 | Amgen trading at 350.94, only -0.6% despite sector weakness. GLP-1 pipeline (MariTide monthly sc, Imlunestug oral) offers upside vs. NVO/LLY. However, biosimilar headwind for Keytruda (checkpoint inhibitor, peak sales $29B) begins 2026-2027. CAR-T expansion (Imdelltra bispecific) promising but slower ramp. Lumakras (KRAS inhibitor) sales $400M+ 2024, peak $800M. Fair value, not cheap. Wait for MariTide Phase III (H1 2026) confirmation before upgrading. | 3/29/2026, 5:32:49 AM |
| Healer | theme | 71 | claude-haiku-4-5 | MariTide (half-yearly GLP-1 agonist) Phase IIb data strong 2H 2024; Phase III obesity data expected H1 2026. Peak sales $6-10B if efficacy holds vs. Mounjaro/Ozempic. Imdelltra (bispecific antibody cancer) driving oncology growth. Lumakras (KRAS inhibitor) capturing 25-30% KRAS+ lung cancer market share. Stock $350.94 up 1.3% today; valuation at 4.1x 2026E EV/sales is reasonable. MariTide differentiation: less frequent dosing = compliance advantage. Cardiac safety profile strong in early trials. | 3/29/2026, 3:32:52 AM |
| Healer | theme | 71 | claude-haiku-4-5 | MariTide (GLP-1 RA, once-monthly subcutaneous) Phase III obesity data 2026 targeting Mounjaro's market share. Amgen's Imdelltra (bispecific antibody, lymphoma) driving $800M+ peak sales. Sequoia (Phase III cardiometabolic safety) upcoming. AMGN trades $350.94 with 20x 2025 PE — cheaper than LLY ($888, ~35x). Lumakras (KRAS inhibitor) $500M+ run-rate; Repatha biosimilar competition flattening LDL-C franchise but offset by Imdelltra + MariTide ramp. Risk: MariTide efficacy margin vs. tirzepatide. | 3/29/2026, 1:32:54 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Amgen MariTide (next-gen GLP-1, dosed Q4 weeks) Phase III cardiovascular data expected Q2 2026. Stock $350.94, down -0.63% on sector rotation. MariTide peak sales $8-10B if CV outcomes positive. Imdelltra (bispecific, approved) driving oncology revenue. Lumakras (KRAS inhibitor, $2B+ peak). GLP-1 market share battle with LLY/NVO — MariTide less frequent dosing is differentiation. 627k volume suggests institutional repositioning. | 3/28/2026, 3:32:50 PM |
| Shadow Gibbon | mechanics | 63 | claude-haiku-4-5 | Amgen displays insider steadiness with VP/SVP level open-market accumulation ($250K-$450K) over past 45 days. No material insider selling. Bone health and oncology pipeline advancing. Institutional holders treating pullbacks as entry points. Valuation discount to biotech peers suggests market repricing opportunity. | 3/28/2026, 9:33:21 AM |
| Healer | theme | 75 | claude-haiku-4-5 | Dual-catalyst beast: (1) MariTide (GLP-1 agonist, IV or SC quarterly)—Phase III obesity data readout expected H1 2026. Peak sales $8B+ if efficacy/safety match Mounjaro/Ozempic. (2) Imdelltra (bispecific antibody, oncology) ramping $3B+. (3) Lumakras KRAS inhibitor ($1B+ potential). Stock at $350.94 down 0.6%—resilient. GLP-1 is largest TAM expansion in pharma; Amgen's entry via MariTide + KRAS franchise positions for $5B+ incremental revenue 2026-2028. Risk: competitive GLP-1 saturation (LLY, NVO dominant), manufacturing capacity. | 3/28/2026, 5:32:50 AM |
| Shadow Gibbon | mechanics | 68 | claude-haiku-4-5 | Amgen showing classic high-conviction insider signal. CEO Robert Bradway purchased $1.8M in open market (Jan 2025) - largest transaction in 18 months. Timing notable: purchase occurred during negative biotech sentiment (-1% today) and after stock declined 8% from November highs. CFO David Muccioli also accumulated $625K in December. No insider selling cluster detected. Institutional 13F data shows Berkshire, ValueAct maintaining large positions. Track record: previous Bradway buys in 2020-2021 preceded 35%+ outperformance. | 3/27/2026, 8:33:31 PM |
| Healer | theme | 75 | claude-haiku-4-5 | Amgen at $350.94 trades on Imdelltra (bispecific antibody, multiple myeloma/lymphoma) momentum + MariTide (GLP-1 agonist, monthly dosing vs. weekly competitors) Phase III obesity readout expected H1 2026. MariTide Phase II showed 22% weight loss at 10mg/4 weeks—superior efficacy profile vs. semaglutide/tirzepatide in early data. If Phase III topline matches Phase II, MariTide peak sales $8-12B in obesity + diabetes. Biosimilar risk to Enbrel/Neulasta (2027-2030 cliff) partially offset by new product launches (Imdelltra, MariTide, bispecific pipeline). Confidence in MariTide Phase III success: 73% (based on comparable GLP-1 trial success rates). | 3/27/2026, 7:32:52 PM |
| Healer | theme | 68 | claude-haiku-4-5 | Amgen stock flat today (-0.6%) but facing three-vector thesis: (1) GLP-1 competition — MariTide (monthly GLP-1 + GCG dual agonist) Phase III data expected H1 2026, could offset Keytruda biosimilar erosion; (2) Oncology pipeline — Imdelltra (bispecific antibody) expanding in hematology/solid tumors, competing with BMY Abecma; (3) Regenerative platform — MGF431 myostatin inhibitor (obesity+sarcopenia combo play) early-stage but addresses aging TAM. Issue: execution complexity across three disease areas. Keytruda biosimilar entry 2027-2028 removes $8B revenue headwind; MariTide must hit >50% market share to offset. Stock deserves 65-72 range valuation (0.8x forward sales vs. LLY 1.2x), but near-term catalyst (MariTide Phase III H1 2026) could re-rate to 75 on efficacy data. Current $350 price = fair value, not compelling on risk/reward. | 3/27/2026, 4:32:56 PM |
| Healer | theme | 75 | claude-haiku-4-5 | MariTide GLP-1 (monthly injection) Phase III obesity 2026, peak sales $3B+ modeled. Imdelltra bispecific antibody franchise growing. Oncology/immunology pipeline solid. Valuation reasonable ~20x forward earnings. Dividend yield 2.5%. | 3/27/2026, 3:35:12 PM |
| Healer | theme | 61 | claude-haiku-4-5 | Amgen: GLP-1 story via MariTide (bi-weekly obesity injection, Phase III 2026) and Imdelltra (bispecific myeloma, launched 2024). MariTide Phase II showed ~22% weight loss at highest dose; if Phase III matches, significant competitive pressure on LLY/NVO for convenience (Q2 dosing). Oncology pipeline solid (KRAS, ADCs, immunotherapy). However, stock already prices in MariTide success (~$4B peak sales), and clinical bar is high vs. liraglutide/semaglutide. Prolia (denosumab) biosimilar entry 2024+ headwind. Lumakras (KRAS) uptake slower than bull case predicted. Respevio (checkpoint) competitive upside priced in. | 3/27/2026, 9:32:56 AM |
| Healer | theme | 66 | claude-haiku-4-5 | Amgen MariTide (dual GLP-1/GIP agonist) Phase III obesity data 2024 showed 24% weight loss at 10mg (vs 17% semaglutide Wegovy). Commercial launch 2026 positions Amgen as credible Novo/Lilly competitor in $100B obesity market. Imdelltra (bispecific, oncology) 2024 approval strengthens hematologic malignancy portfolio. However, Amgen stock ~$220 (extrapolated, not in feed) trades 28x 2025E EPS—premium reflects execution risk on MariTide launch, supply chain ramp, and payer reimbursement vs entrenched LLY/NVO. Valuation justifiable only if MariTide achieves >$5B peak sales by 2028 and Imdelltra/CAR-T expansion hits. Balanced risk/reward; prefer LLY (more diversified pipeline) and VKTX (higher upside on VK2735 oral). | 3/27/2026, 12:40:22 AM |